Shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) are going to reverse split on Thursday, August 1st. The 1-12 reverse split was announced on Thursday, August 1st. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 1st.
Evoke Pharma Stock Performance
EVOK stock traded down $0.08 during midday trading on Tuesday, reaching $0.42. 112,058 shares of the company’s stock traded hands, compared to its average volume of 42,557. The company has a 50-day moving average price of $0.52 and a two-hundred day moving average price of $0.57. Evoke Pharma has a 52 week low of $0.36 and a 52 week high of $1.67. The firm has a market capitalization of $3.59 million, a PE ratio of -0.23 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The business had revenue of $1.74 million for the quarter.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on EVOK
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- What is the Australian Securities Exchange (ASX)
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How to Invest in Blue Chip Stocks
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.